The present study is aimed at evaluating the impact of a switch from Prograf to Advagraf on
renal function, trough tacrolimus levels, drug-related adverse effects and adherence in
stable recipients of kidney-pancreas transplants. MPA pharmacokinetics will also be
evaluated. The results of this study have the potential to change current practice.